NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$13.77
+0.34 (+2.53%)
Close of Nov 06, 2026 · end-of-day data
LFST 8-K filings in 2025
Every material Form 8-K Lifestance Health filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LifeStance reported third-quarter 2025 results on November 6, 2025, with revenue of $363.8 million, up 16% from a year earlier, and net income of $1.1 million compared with a net loss of $6.0 million in the prior-year quarter. The company raised its full-year 2025 Adjusted EBITDA guidance to $146 million to $152 million and raised the midpoint of its Center Margin expectations, while reiterating its full-year revenue outlook of $1.41 billion to $1.43 billion.
Q3 2025 revenue of $363.8 million, up 16%; clinician base rose 11% to 7,996.
Net income of $1.1 million versus a $6.0 million net loss a year earlier; Adjusted EBITDA of $40.2 million, up 31%.
Full-year 2025 Adjusted EBITDA guidance raised to $146 million to $152 million; revenue guidance reiterated at $1.41 billion to $1.43 billion.
Fourth-quarter 2025 outlook: total revenue of $368 million to $388 million and Adjusted EBITDA of $37 million to $43 million.
LifeStance Health Group said director William Miller resigned from its board and all committees, effective immediately, and that the resignation was not due to any disagreement with the company. The board then appointed Sarah Personette as a director, granting her 74,766 restricted stock units that vest based on time and performance, subject to her continued board service.
William Miller notified the board of his resignation on August 19, 2025, effective immediately
The company stated the resignation was not the result of any disagreement with Mr. Miller
Sarah Personette was appointed a director on August 20, 2025
Ms. Personette received an initial award of 74,766 restricted stock units under the 2021 Equity Incentive Plan
LifeStance Health Group reported second-quarter 2025 revenue of $345.3 million, up 11% from a year earlier, and a net loss of $3.8 million, narrowed from $23.3 million. The company reiterated its full-year 2025 revenue outlook of $1.40 billion to $1.44 billion and raised its full-year Adjusted EBITDA and Center Margin expectations.
Q2 revenue was $345.3 million, up 11% from $312.3 million; visit volumes rose 12% to 2.2 million.
Net loss was $3.8 million versus $23.3 million a year earlier; Adjusted EBITDA rose 19% to $34.0 million.
Full-year 2025 Adjusted EBITDA raised to $140 million to $150 million; Center Margin raised to $441 million to $465 million.
Third-quarter 2025 revenue is expected at $345 million to $365 million.
LifeStance Health Group said Vaughn Paunovich will join as Chief Technology Officer effective June 9, 2025, succeeding Chief Digital Officer Pablo Pantaleoni, who is leaving on July 1, 2025. The filing also describes a separation agreement for Pantaleoni with severance-type payments and equity vesting, subject to a release and continued compliance with restrictive covenants.
Vaughn Paunovich becomes Chief Technology Officer effective June 9, 2025; he previously served as EVP, Enterprise Platforms at Amwell.
Pablo Pantaleoni's departure takes effect July 1, 2025 (the Transition Date).
Pantaleoni will receive an amount equal to his annual base salary in two installments, 12 months of COBRA premiums, and vesting of certain restricted stock units after January 1, 2026.
CEO Dave Bourdon said Paunovich will lead the company's end-to-end technology strategy.
LifeStance Health Group reported first-quarter 2025 revenue of $333.0 million, up 11% from $300.4 million a year earlier, and net income of $0.7 million compared with a net loss of $21.1 million in the prior-year quarter. The company reaffirmed its full-year 2025 guidance for revenue, Center Margin and Adjusted EBITDA, and gave second-quarter revenue guidance of $332 million to $352 million.
Q1 2025 revenue of $333.0 million, up 11%; Adjusted EBITDA of $34.6 million, up 25%
Net income of $0.7 million versus a net loss of $21.1 million in Q1 2024
Net cash used in operations was $3.1 million in Q1; cash ended the quarter at $134.3 million
Full-year 2025 guidance reiterated: revenue $1.40 billion to $1.44 billion; Adjusted EBITDA $130 million to $150 million
LifeStance's board promoted David Bourdon, the company's CFO since 2022, to Chief Executive Officer effective March 3, 2025, succeeding Kenneth Burdick, who is retiring as CEO and will serve as Executive Chairman. Ryan McGroarty was named Chief Financial Officer and Treasurer effective March 17, 2025, to succeed Bourdon in that role. The filing does not include financial results.
Bourdon becomes CEO effective March 3, 2025, with a $700,000 annual base salary and a target bonus of 100% of base salary.
Burdick, CEO since 2022, retires as CEO and becomes Executive Chairman with a $200,000 annual base salary.
McGroarty becomes CFO effective March 17, 2025, with a $550,000 base salary, a target bonus of 85% of base salary, and a $570,000 one-time signing bonus.
McGroarty's one-time equity award has an aggregate target grant date value of approximately $5,000,000.
LifeStance Health Group reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue grew 19% for the full year to $1.25 billion, and the full-year net loss narrowed to $57.4 million from $186.3 million in 2023. The company also expects 2025 revenue of $1.40 billion to $1.44 billion and Adjusted EBITDA of $130 million to $150 million.
Q4 2024 revenue was $325.5 million, up 16%; full-year revenue was $1.25 billion, up 19%.
Q4 2024 net loss was $7.1 million versus $45.0 million a year earlier; full-year net loss was $57.4 million versus $186.3 million.
Full-year 2024 Adjusted EBITDA was $119.7 million, up 103%; Free Cash Flow was $85.7 million.
2025 guidance: revenue of $1.40 billion to $1.44 billion, Center Margin of $440 million to $464 million, Adjusted EBITDA of $130 million to $150 million; Q1 2025 revenue of $320 million to $340 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lifestance Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →